Introduction
============

Kidney transplantation is now the standard of care for many human immunodeficiency virus (HIV)-infected patients with end-stage renal disease (ESRD). Early outcomes using HIV-negative donors and carefully selected HIV-positive ESRD patients are favourable, with rates of graft survival similar to those observed in HIV-uninfected kidney transplant recipients \[[@sfx109-B1]\]. However, there is a relative shortfall in donated organs that affects all transplant candidates, including those with HIV. One way to help alleviate this shortage would be to enable the allocation of organs from HIV-infected deceased donors to HIV-infected patients on the transplant waiting list. These organs would otherwise be discarded. The precedent for this approach was set in South Africa, where promising short-term outcomes have been reported in a small number of HIV-infected recipients of kidney transplants from HIV-infected donors \[[@sfx109-B2]\]. We sought to replicate this experience in the UK, and here we report the UK's first cases of kidney transplantation between HIV-positive donors and recipients.

Materials and methods
=====================

Donor and recipient selection criteria were as follows: for the donor, stable and well-characterized HIV infection (HIV viral load \<50 copies/mL; CD4 count \>200 cells/mm^3^) for at least 6 months prior to brain injury; no history of virological failure or drug resistance; preferably where information about the donor virus (such as historical genotype patterns and current viral load) could be obtained. The potential for donor coinfection with hepatitis C virus (HCV) was considered, and, given that HIV/HCV-coinfected kidney transplant recipients have poorer graft outcomes than HIV mono-infected recipients \[[@sfx109-B3]\], HIV/HCV coinfected donors were excluded. Potential transplant recipients were identified as those with a history of compliance with HIV treatment and well-controlled HIV infection (HIV viral load \<50 copies/mL; CD4 count \>200 cells/mm^3^) for at least 6 months prior to admission to the transplant waiting list. This is in accordance with current UK guidance \[[@sfx109-B4]\]. Candidates for transplantation were counselled about the potential risks of HIV-infected organ donation, including risks of superinfection with a recombinant virus with loss of virological control or transmission of viral resistance, higher rejection rates, interaction between donor antiretroviral medications and recipient immunosuppression and transmission of other (opportunistic) infections from the donor, in comparison with the risks of remaining on the transplant waiting list. Suitable candidates gave informed consent both at the time of listing and prior to transplantation. The study was approved internally by the departmental governance and strategy group and externally by the Kidney Advisory Group of NHS Blood and Transplant.

Results
=======

The donor was a 55-year-old white male. The cause of death was brain death following a subarachnoid haemorrhage. The patient was known to have had HIV infection for the preceding 7 years. Following an episode of pneumocystis pneumonia 6 years previously the patient had commenced antiretroviral treatment with tenofovir, emtricitabine and efavirenz and this remained unchanged thereafter. The HIV viral load was \<50 copies/mL for the preceding 3 years; the CD4 count had been \>200 cells/mm^3^ for the preceding 6 years. The patient's HIV physician reported them to be adherent with medication and well for the preceding 6 years. There was no history of opportunistic infection or malignancy. Coinfection with HCV was excluded. Pre-mortem kidney function was normal and there was no dipstick proteinuria. Both kidneys were accepted and implanted into two local recipients with informed consent: a 60-year-old Black Caribbean male active 563 days on the deceased donor waiting list (Recipient 1) and a 45-year-old Black Caribbean male active 306 days on the deceased donor waiting list (Recipient 2). The cold ischaemic times were 18 h and 22 h 40 min, respectively. Induction immunosuppression was with basiliximab and methylprednisolone, and maintenance immunosuppression with ciclosporin (target levels 200--300 µg/L for the first month post-transplant), mycophenolate mofetil and corticosteroids. Pre-implantation biopsies were taken from both kidneys and showed mild acute tubular injury but were otherwise normal.

Recipient 1 had ESRD secondary to diabetic nephropathy. His preoperative antiretroviral regimen was lamivudine, abacavir, darunavir and ritonavir. His preoperative CD4 count was 203 cells/mm^3^ and his HIV viral load was 21 copies/mL. Postoperatively, the patient experienced oliguric delayed graft function, and required haemodialysis. A kidney biopsy on postoperative Day 5 showed acute T-cell-mediated rejection with arteritis. The patient was treated with a 10-day course of anti-thymocyte globulin and responded well, with creatinine eventually settling at 200 µmol/L \[corrected estimated glomerular filtration rate (eGFR) 38 mL/min\], and remaining stable thereafter.

Recipient 2 had ESRD secondary to HIV nephropathy and hypertension. His preoperative antiretroviral regimen was darunavir, ritonavir, dolutegravir and lamivudine. His preoperative CD4 count was 398 cells/mm^3^ and his HIV viral load was 33 copies/mL. Postoperatively he achieved immediate allograft function, and was discharged on Day 8 post-transplant, with a creatinine of 248 µmol/L (corrected eGFR 31 mL/min). His function continued to improve and by 4 weeks post-transplantation, had settled to a baseline creatinine of 150 µmol/L (corrected eGFR 56 mL/min).

Both patients remain well after 2 years of follow-up. Neither patient has experienced loss of virological control, fall in CD4 count, opportunistic infection or any further rejection episodes. There has been no change in antiretroviral medication. Clinical and evolutionary data are summarized in Table [1](#sfx109-T1){ref-type="table"}. Table 1.Clinical and evolutionary data of the kidney transplant recipientsClinical dataRecipient 1Recipient 2Age (years)6045GenderMaleMaleImmunosuppressive treatmentCiclosporinCiclosporinMycophenolate mofetilMycophenolate mofetilSteroidsSteroidsAntiretroviral treatmentLamivudineAbacavirLamivudineDolutegravirDarunavirDarunavirRitonavirRitonavirEpisodes of acute rejection10CD4 and CD8 counts (cells/mm^3^)CD4CD8CD4CD8 At baseline203386398312 At 6 months3511126330276 At 12 months3061030202235 At 24 monthsNot availableNot available597497Plasma HIV viral load (copies/mL) At baseline2133 At 6 monthsNot detected\<20 At 12 monthsNot detected37 At 24 months34Not detectedeGFR (mL/min/1.73 m^2^) At baseline137 At 6 months4939 At 12 months5137 At 24 months3935Serum creatinine (µmol/L) At baseline507869 At 6 months161206 At 12 months156218 At 24 months194228Proteinuria (mg/mmol) At baseline1+ on dipstick1+ on dipstick At 6 months1+ on dipstick1+ on dipstick At 12 months3827 At 24 months131+ on dipstick

Of note, Muller *et al.* described early changes related to HIV-associated nephropathy in three kidney transplant recipients who received organs from HIV-positive donors with no evidence of nephropathy on baseline biopsy \[[@sfx109-B2]\]. In line with local policy, Recipient 1 did not undergo protocol biopsy because of well preserved and stable allograft function. Recipient 2 underwent a protocol biopsy at 6 months post-transplant for reduced allograft function. This showed no features suggestive of HIV-associated nephropathy, and both recipients have maintained stable allograft function without significant proteinuria after 2 years of follow-up. The role and optimal frequency of protocol biopsy in recipients of kidney transplants from HIV-positive donors remains to be determined.

Discussion
==========

Kidney transplantation is now the standard of care for carefully selected patients living with HIV infection and ESRD in the current era of highly active antiretroviral therapy. Prospective cohort studies report similar patient and graft survival compared to HIV-negative kidney transplant recipients. Drawing on favourable experience in South Africa we have undertaken the first UK kidney transplants between HIV-infected individuals with excellent outcomes after 2 years of follow-up. Our results and others' \[[@sfx109-B5]\] demonstrate that kidney transplantation between carefully selected HIV-infected donors and recipients is a safe and effective treatment option with the potential to expand the organ donor pool for HIV-positive patients with end-stage kidney disease.
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